POPs’ effect on cardiometabolic and inflammatory profile in a sample of women with obesity and hypertension by Ferro, Ana et al.
POPs’ effect on cardiometabolic and inflammatory 
profile in a sample of women with obesity and 
hypertension 
Ana Ferro, Diana Teixeira, Diogo Pestana, Rosário Monteiro, Cristina C.Santos, Valentina F. 
Domingues, Jorge Polónia & Conceição Calhau 
 
Abstract 
Persistent organic pollutants (POPs) are man-made compounds with metabolic disruption 
impact. We investigated the effect of POP exposure in the cardiometabolic and 
inflammatory profile in a population of women with obesity and hypertension. In 43 
premenopausal women (22 treated vs. 21 nontreated) undergoing bariatric surgery, blood 
and adipose tissue samples (visceral (vAT) and abdominal subcutaneous (scAT)) were 
collected. Median concentrations of ∑HCH and ∑POPs in vAT were significantly higher 
in treated women. VAT ∑HCH and scAT ∑HCH and ∑POPs concentrations were 
positively correlated with systolic blood pressure in the non-treated group. Our findings 
suggest that exposure to POPs and its accumulation in vAT and circulating in plasma may 
be associated to a higher cardiovascular risk in women with obesity and hypertension, 
with or without antihypertensive treatment. 
Keywords: Cardiometabolic risk, hypertension, inflammation, obesity, persistent organic 
pollutants 
Introduction 
Incidence and prevalence of obesity is increasing worldwide and it is associated with 
several disorders, such as diabetes, hypertension, cardiovascular and liver disease and 
neoplastic disease.1–3 Despite its multifactorial etiology, it has been suggested the 
influence of certain environmental agents described as persistent organic pollutants 
(POPs) that have endocrine disruption effects.4–6 These POPs are man-made compounds 
derived primarily from industrial activities. POPs’ combinations contaminate the air, soil 
and water; however, humans’ exposition occurs primarily through dietary sources, 
especially fatty foods of animal origins, such as milk, meat and fish.7 These synthetic 
chemicals are or were used as pesticides, plasticizers, antimicrobials, among others.8 
The association of obesity and high blood pressure increases the probability of numerous 
cardiovascular events. Hypertension has many known risk factors, for instance genetic 
influence, age, race, gender, smoking, stress, renal abnormalities and endocrine function, 
diet, and exercise.9 This condition is a major risk factor for stroke, coronary events and 
heart and renal failure.10 Nevertheless, there are some studies that suggest that exposure 
to POPs may be an additional factor to hypertension development in a younger age and a 
greater severity of this condition.9,11 
POPs are lipophilic substances environmentally and biologically persistent, which leads 
to their bioaccumulation predominantly in the adipose tissue (AT).5,6,12 Despite the 
protective profile of this preferential bioaccumulation, it soon becomes deleterious, 
because AT turns into a continual source of internal exposure to POPs, besides its role in 
metabolism. For instance, they are called environmental “obesogens” because they 
inappropriately regulate and promote lipid accumulation and adipogenesis.6 
Even though the relationship of POPs and its influence with cardiovascular disease and 
metabolic syndrome has been studied by different groups, there haven’t been many 
studies toward hypertension.5,11,13–19 Indeed, although recent studies have observed an 
association between exposition to POPs and higher prevalence of hypertension, with 
putative disruption of normal blood pressure levels and increased odds of 
hypertension.20,21 Further observational studies are still needed to better understand this 
potential effect. Putative biological mechanisms could involve vascular dysfunction and 
cardiac hypertrophy.22–24 
Thus, it will be relevant to investigate the effect of POP exposure in the cardiometabolic 
and inflammatory profile in a population of women with obesity and hypertension, and 
whether the presence, or absence, of an antihypertensive therapy influence the observed 
effects. 
Materials and methods 
Study participants 
This study was conducted in 43 premenopausal women with obesity and hypertension 
(22 treated with antihypertensive drugs and 21 non-treated for this condition) with an age 
range of 22–59 years old undergoing bariatric surgery at the General Surgery Department, 
S. João Hospital (Porto, Portugal). These patients met the criteria for bariatric surgery 
according to the country’s Department of Health latest criteria: BMI (body mass 
index) ≥ 40 kg m−2 or BMI ≥35 kg m−2 with at least one comorbidity, such as 
hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea syndrome. These 
patients had diagnosed hypertension and the information about the treatment or absence 
of treatment is according to data collected from their clinical information. Over this article 
we sorted the sample into two different clusters named “treated women” (women with 
obesity and hypertension under antihypertensive therapy) and “nontreated women” 
(women with obesity and hypertension without antihypertensive therapy prescribed). In 
means of comparison, it was also analyzed a sample of 19 women with obesity, but 
without hypertension that met the criteria mentioned above. In this secondary analysis, it 
was performed a comparison between the group of women without hypertension and the 
group of nontreated women and between the group of women without hypertension and 
the group of treated women. All participants were recruited between January 2010 and 
June 2011 and signed informed consent to participate in the study. This investigation was 
conducted according to the Declaration of Helsinki and approved by the Hospital’s Ethics 
Committee. Socio-demographic characteristics, anthropometric characteristics, clinical 
history, life-style factors, parity and occupation were collected from the Medical Support 
System of S. João Hospital (Porto, Portugal). 
Clinical and biochemical parameters 
At baseline were measured anthropometric parameters, adiposity-related markers and 
various clinical variables. BMI (kg m−2) was calculated from the measured weight and 
height both pre-operatively. Blood samples were collected after an overnight fast and 
analyzed by the Department of Clinical Pathology of the S. João Hospital (Porto, 
Portugal). Then measures of insulin resistance (HOMA-IR) and pancreatic beta cell 
function (HOMA-B) were assessed with the homeostatic model assessment (HOMA2).25 
Routine serum chemistries were measured using conventional methods with an Olympus 
AU5400® automated clinical chemistry analyzer (Beckman-Coulter®, Izasa, Porto, 
Portugal). The biological parameters evaluated included fasting blood glucose and 
insulin, lipid profile [total cholesterol, high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol and triglycerides] and high-sensitivity C-reactive 
protein (hsCRP). Low-density lipoprotein (LDL) cholesterol was calculated according to 
Friedewald's equation.26 Finally, we used the Framingham risk score to estimate the 10-
year CVD risk (person’s chance of developing cardiovascular disease in the next 
10 years) of these individuals.27 
All variables presented below refer to measurements made at baseline. 
Adipose tissue management 
Human AT samples were collected from visceral (vAT) and abdominal subcutaneous 
(scAT) tissue during bariatric surgery. These samples were coded, processed and stored 
at −80 °C. 
Adipocyte size was measured as previously described by Pestana et al.5 The procedure 
included fixation in buffered formaldehyde 10% for at least 48 h at 4 °C, dehydration and 
finally embedded in fresh paraffin. Using a Leica® Microtome (RM2125RT, Lisbon, 
Portugal), it was obtained 3-µm-thick sections that were stained with hematoxylin-eosin 
to assess morphology. Digital images were acquired with a fluorescence microscope 
(Nikon Eclipse 50i®, Melville, USA), at a magnification of 200× from five randomly-
selected fields. Then the area of the adipocytes, ∼90 adipocytes for vAT and 60 
adipocytes for scAT, was measured with ImageJ software® (National Institute of Health, 
Bethesda, USA). 
Assessment of POPs concentrations in plasma and adipose tissue 
It was studied the presence of thirteen different POPs such as aldrin, dieldrin and endrin 
[bought from Pestanal Fluka® (Madrid, Spain)], hexachlorobenzene (HCB) and 
hexachlorocyclohexane lindane (HCH Lindane) [bought from Pestanal Riedel-de Haën® 
(Madrid,Spain)], Σ hexachlorocyclohexane (ΣHCH) (sum of α-HCH, β-HCH and δ-
HCH) [obtained from Sigma–Aldrich® (Madrid,Spain)]. EndosulfanI, endosulfanII, 
methoxyclor, 2, 3, 7, 8-tetrachlorodibenzodioxin (TCDD), p,p′-dichlorodiphenyldichlor-
oethane (p,p′-DDD) and p,p′-dichlorodiphenyltrichloroethane (o,p′-DDT) [purchased 
from Supelco® (Madrid,Spain)]. p,p′-dichlorodiphenyldichloroethylene (p,p′-DDE) 
[obtained from ChemService® (WestChester, United States of America (USA)]. 
The POPs aforementioned were quantified in plasma samples stored at −80 °C collected 
preoperatively. The samples were analyzed using the methodology described by Covaci28 
with adjustments described by Teixeira16 namely the involvement of solid-phase 
extraction and final determination using a gas chromatograph coupled to an electron 
capture detector (GC-ECD). Results were expressed as nanograms per milliliter of plasma 
and represent a mean of three individual injections of the same sample. 
In turn, POPs’ analysis in AT was performed according to the method described by 
Fernandes et al.29 The procedure included standardized extraction of 200 mg of AT, clean 
up using solid phase extraction columns Strata C18-E (SPE, 500 mg/3 mL, 55 mm), 
purchased from Phenomenex (Torrance, CA) and quantification by gas chromatography 
with electron-capture detection (GC-ECD) a Shimadzu GC-2010, equipped with a 
capillary column of 30 m ZB-XLB (0.25 mm i.d. 0.25 μm film thickness, Zebron-
Phenomenex). 4-4′-dichlorobenzophenone was used as internal standard. The results 
were expressed as ng of POPs/g of fat and are a mean of three individual determinations 
of the same sample. 
The methods were validated by measuring linearity and limits of detection (LOD) and 
quantification (LOQ)29 according to ICH guidelines (ICH,2005). For analysis purposes, 
only the POPs measured above LOD were considered (positive samples). Agreement in 
the retention time in the sample and in the reference standard was also required to confirm 
a positive result. 
Cytokines measurement 
Interleukin (IL) 6, IL-10, monocyte chemotatic protein-1 (MCP-1) concentrations in 
plasma were measured using, respectively, LEGEND MAXTM Human IL-6, IL-10, 
MCP-1 ELISA kits (BioLegend, San Diego, CA), according to the manufacturer’s 
instructions. 
Statistical analyses 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS, 
22.0 version statistical software, IBM Corp®, New York, USA). Because of the skewed 
distribution of data, variables are summarized with frequencies, median (minimum, 
maximum). Mann–Whitney test was used to compare the clinical and biological 
characteristics and the concentration of the different POPs in the different depots between 
treated and non-treated women for hypertensive disease. To compare women with or 
without hypertension, either with or without treatment, Mann–Whitney test with 
Bonferroni correction for multiple comparisons was used. 
The association between POPs concentration in vAT, scAT and plasma and the various 
clinical parameters was estimated by Spearman correlation coefficients. All tests were 
two-tailed and p < 0.05 were regarded as significant. 
Although the sum of POPs was calculated by the sum of the thirteen pollutants above-
mentioned, it was only possible to assess correlations with the sum of HCH, p,p′-DDE 
and the sum of POPs, since the others isolated compounds investigated had low detection 
frequencies. 
Results 
Clinical and biological markers 
The comparison of the clinical and biological parameters between treated and non-treated 
women is shown in Table 1. Because our cohort is a group of premenopausal obese 
women, it was not expected to be any significant difference related to age. Regarding the 
anthropometrics, there was no statistically significant difference between the two groups 
in BMI, waist/hip ratio or vAT adipocyte area, however scAT adipocyte area was 
significantly higher in nontreated women (median =  5323.3 vs median =  6271.8 µm2, 
p = 0.048). Neither the lipid profile nor glucose homeostasis or hepatic function presented 
any significant difference between the two clusters. Regarding blood pressure, there was 
no significant difference between treated or non-treated women with hypertension. In 
addition, it was found no significant difference in IL-6, IL-10, MCP-1, and C-reactive 
protein between the two clusters. The comparison of 10-year cardiovascular disease 
(CVD) risk revealed no statistically significant difference. 
Table 1. Clinical and biological characteristics of the patients. 
 
BMI, body mass index; CVD, cardiovascular disease; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; 
HOMA-IR, homeostasis model of assessment - insulin resistance; HOMA2-B, homeostasis model of assessment beta 
cell function; IL, interleukin; LDL, low-density lipoprotein; MCP1, monocyte chemotatic protein-1; vAT, visceral 
adipose tissue; scAT, subcutaneous adipose tissue. 10-Year CVD risk calculated according to D'Agostino et al.27 
Statistical analysis with Mann-Whitney test: *p < 0.05. 
POPs in plasma 
The comparison of the measurement of POPs between treated and non-treated women 
with hypertension is shown in Table 2. Among the selected POPs, in both groups the most 
frequently detected compound in plasma was ∑HCH (sum of α-HCH, β-HCH and δ-
HCH) present in 86.4% of the samples in the treated group and 90.5% in the nontreated 
group. p,p′-DDE was not found in the plasma of neither groups. There was no statistically 
significant difference between the two groups. Concentrations of the sum of all POPs 
present in plasma did not differ between treated and nontreated women (median = 47.53 
vs median = 37.37 ng mL−1, p = 0.432). 
Table 2. Persistent organic pollutants (POPs) levels in plasma (ng mL−1) 
and in both visceral (vAT) and subcutaneous (scAT) adipose tissue (ng/g of 
fat) of the 43 patients. 
 
a percentage of the total number of positive samples. All data are medians (minimum, maximum). ∑HCH, sum of 
hexachlorocyclohexane; p,p'-DDE, p,p'-dichlorodiphenyldichloroethylene. 
Statistical analysis with Mann-Witney: *p < 0.05. 
POPs in vAT and scAT 
Examining the presence of POPs both in vAT and scAT (Table 2), it was possible to 
assess that, in the treated group, the percentage of samples with detectable concentration 
of POPs was 90.9% with median values of 251.08 (ranging from 23.96 to 687.18) ng g−1 
of fat in vAT and 100% with median values of 99.10 (ranging from 16.78 to 440.35) 
ng g−1 of fat in scAT. In nontreated women, the percentage of samples with detectable 
concentration of these compounds was 90.5% with median values of 68.84 (ranging from 
11.25 to 453.92) ng/g of fat in vAT and 95.2% with median values of 70.03 (ranging from 
3.74 to 309.10) ng g−1 of fat in scAT. The most frequently detected compound was ∑HCH 
present in 86.4% and 81.0% for treated and non-treated women, respectively, in vAT. In 
scAT, ∑HCH was also the most frequently detectable compound with 95.5% and 90.5% 
detection rates in treated and non-treated women respectively. In treated women, p,p′-
DDE was detected in 36.4% of the samples in vAT and 40.9% of the samples in scAT. In 
nontreated women, the prior compound was detected in 9.5% in vAT and 23.8% in scAT. 
Concentrations of ∑HCH (median = 202.77 vs median = 56.03 ng g−1, p = 0.045) and 
concentrations of POPs (median = 251.08 vs median = 68.84, p = 0.016) in vAT were 
significantly higher in treated women. Concerning scAT, there was no statistically 
significant difference between the two groups. 
Association between POPs and cardiometabolic risk and inflammation in 
treated women 
The association between POPs levels and the patients’ clinical and biochemical 
parameters is shown in Table 3. The plasma ∑HCH concentration was significantly and 
inversely correlated with HbA1c and the ratio IL-6/IL-10 and the plasma ∑POPs 
concentration was inversely correlated with HOMA-IR. Concerning vAT, the presence 
of ∑HCH was inversely correlated with plasma albumin and p,p′-DDE was positively 
correlated with HbA1c and plasma IL-10. VAT ∑POPs was positively correlated with 
10-year CVD risk and the count of plasma monocytes. Regarding scAT, the ∑HCH 
concentration was positively correlated with scAT adipocyte area and inversely correlated 
with plasma AST, p,p′-DDE was positively correlated with plasma MCP-1 and the 
∑POPs concentration was positively correlated with scAT adipocyte area and inversely 
correlated with plasma AST and G-GT. 
Table 3. Correlation of clinical and biological characteristics with the sum 
of hexachlorocyclohexane (∑HCH), p,p'-dichlorodiphenyldichloroethylene 
(p,p'-DDE) and persistent organic pollutants (POPs) levels in visceral 
(vAT) and subcutaneous (scAT) adipose tissue (ng/g of fat) and plasma 
(ng mL−1) of treated women. 
 
AST, aspartate transaminase; BP, blood pressure; CVD, cardiovascular disease; G-GT, gamma-glutamyl 
transpeptidase; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model of 
assessment - insulin resistance; IL, interleukin; LDL, low-density lipoprotein; MCP1, monocyte chemotatic protein-1; 
scAT, subcutaneous adipose tissue. 10-Year CVD risk calculated according to D'Agostino et al.27 
Statistical analysis with spearman’s correlation: *p < 0.05 and **p < 0.01. 
 
Association between POPs and cardiometabolic risk and inflammation in 
nontreated women 
The association between POPs levels and the patients’ clinical and biochemical 
parameters is shown in Table 4. The plasma ∑HCH concentration was significantly and 
inversely correlated with HDL cholesterol and positively correlated with LDL 
cholesterol, plasma IL-10 and 10-year CVD risk. No significant correlation was found 
between plasma ∑POPs concentration and the different clinical criteria in non-treated 
women. VAT ∑HCH concentration was positively correlated with systolic blood 
pressure. ScAT ∑HCH and ∑POPs concentrations were positively correlated with 
systolic blood pressure. 
Table 4. Correlation of clinical and biological characteristics with the sum 
of hexachlorocyclohexane (∑HCH), p,p'-dichlorodiphenyldichloroethylene 
(p,p'-DDE) and persistent organic pollutants (POPs) levels in visceral 
(vAT) and subcutaneous (scAT) adipose tissue (ng/g of fat) and plasma 
(ng/mL) of nontreated women. 
AST, aspartate transaminase; BP, blood pressure; CVD, cardiovascular disease; G-GT, gamma-glutamyl 
transpeptidase; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model of 
assessment - insulin resistance; IL, interleukin; LDL, low-density lipoprotein; MCP1, monocyte chemotatic protein-1; 
scAT, subcutaneous adipose tissue. 10-Year CVD risk calculated according to D'Agostino et al.27 
Statistical analysis with spearman’s correlation: *p < 0.05 and **p < 0.01. 
 
Comparison with women without hypertension 
In addition to the previously described, it was performed a comparison of the clinical and 
biological parameters between a sample of 19 women with obesity without hypertension 
and the group of non-treated women, represented by P1, and the group of treated women, 
represented by P2. The results are shown in Table 5. In a broader perspective, it was 
observed a statistically significant difference regarding the duration of obesity between 
women without hypertension and both groups with hypertension, non-treated women 
(median = 13.0 vs median = 19.0, p = 0.030) and treated women (median = 13.0 vs 
median = 19.0, p = 0.006). As it was expected, blood pressure (BP) is significantly higher 
in women with hypertension, either with or without treatment for systolic (p ≤ 0.001, 
p = 0.024) and diastolic BP (p ≤ 0.001, p = 0.012). Concerning 10-year CVD risk, it was 
significantly higher in women with hypertension despite the presence of treatment 
(p = 0.048, p ≤ 0.001). Focusing on the comparison between women without hypertension 
and treated women with hypertension, it was found that treated women were significantly 
older than women without hypertension (median = 31.0 vs. median = 40.5, p ≤ 0.001). It 
was also noted that HbA1c is statistically higher in treated women (median = 5.3 vs. 
median = 5.7, p ≤ 0.001). Neither groups revealed no statistical significant difference in 
other parameters. 
Table 5. Clinical and biological characteristics of the patients. 
 
P1: nonhypertensive women vs. nontreated hypertensive women; P2: nonhypertensive women vs. treated 
hypertensive women. 
BMI, body mass index; CVD, cardiovascular disease; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; 
HOMA-IR, homeostasis model of assessment - insulin resistance; HOMA2-B, homeostasis model of assessment beta 
cell function; IL, interleukin; LDL, low-density lipoprotein; MCP1, monocyte chemotatic protein-1; vAT, visceral 
adipose tissue; scAT, subcutaneous adipose tissue. 10-Year CVD risk calculated according to D'Agostino et al.27. 
Statistical analysis with Mann-Whitney test with bonferroni correction for multiple comparisons: *p < 0.05. 
 
The comparison of the measurement of POPs between women without hypertension and 
treated women is shown in Table 6. The comparison with the group of nontreated women 
revealed no statistically significant results. Among the selected POPs, in both groups the 
most frequently detected compound in plasma was ∑HCH present in 86.4% of the 
samples in the treated group and 52.6% in the group without hypertension. p,p′-DDE was 
not found in the plasma of neither groups. It was found that the plasmatic levels of ∑HCH 
and ∑POPs were significantly higher in the group of treated women with hypertension 
comparing to women without hypertension – (median = 8.72 vs. median = 21.64 ng mL≤, 
p = 0.018), (median = 32.61 vs. median = 47.53 ng mL≤, p = 0.015), respectively. Despite 
it was feasible to measure the concentration of POPs in AT in both groups, there was no 
statistically significant differences between them. Also comparing the group without 
hypertension with the non-treated group with hypertension, there were no differences to 
report. 
Table 6. Persistent organic pollutants (POPs) levels in plasma (ng/mL) and 
in both visceral (vAT) and subcutaneous (scAT) adipose tissue (ng/g of fat) 
of the 43 patients. 
 
a- percentage of the total number of positive samples. All data are medians (minimum, maximum). ∑HCH, sum of 
hexachlorocyclohexane; p,p'-DDE, p,p'-dichlorodiphenyldichloroethylene. 
Statistical analysis with Mann-Witney with bonferroni correction for multiple comparisons: *p < 0.05. 
Discussion 
In the present study, we present a comparison between the cardiometabolic and 
inflammatory profile of women with obesity and hypertension with or without 
antihypertensive treatment. The absence of treatment may have many explanations. This 
cohort could only have obesity as cardiovascular risk factor and mild hypertension or high 
normal blood pressure (BP) or white-coat hypertension and, as a first step, the physician 
could attempt life style changes, for a suitable period of time.10 This specific population 
was already at risk of developing metabolic syndrome, since they had class II or III 
obesity undergoing bariatric surgery. This metabolic surgery promotes weight loss and 
improvement or resolution of comorbid risk factors and cardiovascular risk.30,31 
Because of the recent studies relating the exposure to certain environmental factors 
(POPs) to metabolic syndrome and increase in cardiometabolic risk,5,16 we thought it 
would be interesting to evaluate the distribution of several POPs in human AT and plasma 
of these two clusters, and its association with cardiometabolic and inflammatory profile 
in premenopausal women with obesity and hypertension. 
Every day, humans are exposed to mixtures of POPs, making it difficult to establish an 
association between body concentration of a single POP and certain comorbidity, possibly 
attributable to the different interactions among several of these compounds, and not 
taking the “cocktail effect” into consideration.32 As endocrine disruptors chemicals 
(EDCs), defined by the World Health Organization (WHO) as “an exogenous substance 
or mixture that alters the function(s) of the endocrine system and consequently causes 
adverse health effects in an intact organism, or its progeny or (sub) populations,”33–35 they 
comprise a vast number of compounds with distinct chemical structures and 
properties.36,37 Indeed, adding a layer of complexity to their effects, these chemicals can 
act through a multiplicity of mechanisms, namely through nuclear receptors, nonnuclear 
steroid hormone receptors,38 nonsteroid receptors (eg, neurotransmitter receptors), orphan 
receptors [such as aryl hydrocarbon receptor (AhR)] and also in pathways related to 
steroid biosynthesis and/or metabolism or on other actions that may impose onto the 
endocrine system, such as oxidative stress, mitochondrial dysfunction and epigenetic 
modifications.39 
We could assess that virtually all subjects present in this study had detectable quantities 
of POPs in the different depots. Also, the concentration of the compounds analyzed in the 
present study (∑HCH and ∑POPs) in vAT was significantly higher in treated women, but 
p,p′-DDE levels were similar in both groups. On the other hand, both POPs concentrations 
in scAT and plasma were similar between the two groups. Although the depot differences 
regarding POP levels is not consistent within the literature,5,16,40–43 the heterogeneous 
distribution verified in this study has also been reported in other studies, suggesting that, 
even though scAT is an accessible compartment for measurement of contamination 
levels, it is not representative of POPs levels in vAT, a highly metabolically active tissue 
associated with metabolic dysregulation.5,16,40,41 In fact, only in nontreated women the 
levels of POPs in both AT depots were positively correlated (RS =  0.534, p < 0.05). POPs’ 
plasmatic levels were also not representative of the other compartments, as POPs levels 
in vAT and scAT were not correlated with plasma POPs in none of the groups (data not 
shown) and some compounds, such as p,p′-DDE, were not detected in these women. This 
could be related to the physicochemical properties of each compound and metabolic rates 
of the subjects in this study. 
Comparing different clinical and metabolic parameters, we observed a significant 
increase in the adipocytes’ area from scAT in the group without treatment. Because 
obesity is characterized by adipocyte hypertrophy and hyperplasia,12,44 this population 
has an overall increase in adipocyte area when compared to lean individuals. However, 
this statistical difference in the, assumingly, “healthier” group, is accordant with a 
protective storage of POPs in this particular type of AT. The lower metabolic activity, 
lipolysis rate and capillary filtration coefficient of scAT comparing to vAT leads to a 
lower release of these pollutants to the bloodstream12,41 and we conjecture that this 
distribution pattern has less repercussions in metabolic function. Because it has an 
increased area, the distribution of POPs in scAT may be more diluted in nontreated 
women, explaining how we obtained lower detection rates in this group. 
Then, we addressed the effects of POPs on metabolism by exploring correlations between 
their concentration and clinical and metabolic parameters. 
Visceral obesity is correlated to the development of several comorbidities such as T2DM, 
dyslipidemia, insulin resistance and cardiovascular disease.45 This appears to originate 
from disturbance in AT function leading to a chronic inflammatory state and to 
dysregulation of the endocrine and paracrine actions of adipocyte-derived factors.46 
Obesity leads to an up-regulation of pro-inflammatory adipokines (eg IL-6 and MCP-1) 
and decrease of anti-inflammatory (IL-10) factors.47 IL-6 contributes to the development 
of insulin resistance, while MCP-1 promotes macrophage accumulation in AT.48,49 
Indeed, our cluster under medical therapy had a significantly higher amount of POPs in 
vAT and we observed that their presence was associated with a higher 10-year CVD risk 
and an increased inflammatory response in favor of an increased account of circulating 
monocytes, possibly migrating to the AT. The concentration of p,p′-DDE was correlated 
with an increase of HbA1c, probably to an increase of insulin resistance, and an increase 
of IL-10. 
On the other hand, we observed a positive correlation between the presence of vAT 
∑HCH and systolic blood pressure in the non-treated group. This was also verified with 
the presence of ∑HCH and ∑POPs in scAT. These associations are suggestive of a 
contribution of these compounds to the development of arterial hypertension, and even, 
its severity. 
In this study, we found interesting results showing clinical correlations with plasmatic 
levels of ∑HCH and of ∑POPs. In the treated group, we found a decreased insulin 
resistance, translated by a decrease of HbA1c and HOMA-IR. This could be partially 
explained by the preferential use of antihypertensive drugs, such as angiotensin receptor 
blockers (ARBs) or calcium channel blockers, which potentially improve insulin 
sensitivity in this specific population in risk of development, or already with, metabolic 
syndrome.10 Attending that most POPs have endocrine disruption effects, some of which 
display estrogenic activity, they were designed as xenoestrogens (XE).50 Several 
researches report that overstimulation of estrogen receptors present in pancreatic β-cells, 
by these particular compounds, may produce an excessive insulin signaling, culminating 
in insulin resistance.51 This suggests that XE may increase insulin resistance and risk of 
developing T2DM primarily by modulating β-cell function.51 Perlstein et al. showed that 
ARB therapy improved pancreatic β-cell function in stage I hypertensive obese patients 
with insulin resistance, even though there were no changes in insulin sensitivity.52 
However, the role of the interaction of these drugs and circulating POPs is yet to be 
explained. Also, it was possible to verify a decrease of IL-6/IL-10 ratio which indicates a 
shift towards an anti-inflammatory response. 
In respect to nontreated women, it was observed several correlations with the plasma 
levels of ∑HCH. First of all, there was a dislipidemic pattern due to a decrease of HDL-
cholesterol and an increase of LDL-cholesterol. Dyslipidemia is a major risk factor for 
cardiovascular disease and related complications.53,54 Low HDL-cholesterol is one of the 
criteria diagnostic of metabolic syndrome, often with normal LDL-cholesterol.13 
Accordingly, there seems to exist an influence of POPs in lipid metabolism, however 
since different POPs may be related to different metabolic traits, it is difficult to study 
this association. Besides, as dyslipidemia is an early manifestation of insulin resistance 
related conditions and it is often detectable before the development of clinical diagnostic 
criteria of T2DM, lipid concentrations may be intermediaries in the associations between 
POPs and type 2 diabetes.55 In addition, it was observed a positive correlation with 10-
year CVD risk, in a population already at risk because of severe obesity and hypertension. 
Because our objective was to evaluate the effects of POPs in a sample of women with 
hypertension, it seemed of interest to assess the concentration of POPs in a similar sample 
without hypertension and compare the same parameters evaluated with the treated and 
non-treated groups with hypertension. 
Several studies evaluated the association between the obesity duration and incident 
hypertension, however although duration of obesity was associated with an increased risk 
of incident hypertension, it is thought that this interaction is attenuated once adjusted for 
BMI.56 Indeed, the sample of women without hypertension revealed less years of obesity 
duration comparing to both groups with hypertension, however there was no significant 
differences when comparing BMI. 
Also, when comparing the group without hypertension with both groups with 
hypertension, as it was expected, the latter had significantly higher 10-year CVD risk, 
despite the presence of treatment. Both hypertension and obesity have been identified as 
independent risk factors for cardiovascular disease57–59 although it appears that the CVD 
risk is significantly higher in overweight/obese patients.58 
It was obtained interesting results, revealing a higher plasmatic circulating concentration 
of ∑HCH and of ∑POPs in the group under medical antihypertensive therapy comparing 
to the group without hypertension. This is in favor of a harmful process ongoing after the 
release of POPs from AT to circulation and perpetuation of its toxic effects in multiple 
areas. It was also noted that HbA1c is statistically higher in treated women, revealing a 
worst metabolic profile in this group. This could be associated with metabolic syndrome 
and even the circulating POPs. It has been associated that elevated circulating levels of 
POPs could be related to hypertension, obesity, diabetes, metabolic syndrome, and 
cardiovascular disease in humans.60–62 
The limitations of this study rest in our small, very specific population, whether 
hypertension control has been optimized, if there is compliance and unawareness of the 
course duration of antihypertensive treatment. As well, the patients were at the “end-of-
line” of obesity treatment which limits the generalization of our findings to the overall 
population. Also, since the data was retrieved from electronic medical records, there is 
no additional information concerning the diagnostic cutoff used, the exact duration of 
hypertension and its multiorganic impact. 
Nonetheless, our study has significant assets regarding the characterization of 
environmental exposures in three tissue compartments (plasma, visceral fat and 
subcutaneous fat) in treated and nontreated women with obesity and hypertension 
undergoing bariatric surgery and analysis of the results according to hypertensive status, 
exploring a differential link to the metabolic abnormalities and cardiovascular risk. 
Conclusion 
Our findings suggest that the exposure of POPs and its accumulation in vAT and 
circulating in plasma may be related to a higher cardiovascular risk in women with obesity 
and hypertension, with or without antihypertensive treatment, respectively. It was also 
verified that in a similar cohort without hypertension, the circulating concentrations of 
POPs were significantly lower than medical treated women with hypertension. Assuming 
that circulating POPs derive from release of vAT,16 detecting concentrations in vAT may 
be useful to determine an earlier use of antihypertensive treatment to attenuate an ongoing 
deleterious process, either related to insulin resistance and T2DM, as cardiovascular 
events such as stroke, coronary events and heart and renal failure. 
Human ethics committee 
The participation of the human subjects did not occur until after informed consent was 
signed. The study protocol was approved by the S. João Hospital’s Ethics Committee 
(Porto, Portugal). 
Abbreviations 
AT adipose tissue 
BMI body mass index 
BP blood pressure 
CVD cardiovascular disease 
POPs persistent organic pollutants 
p,p′-DDE p,p′-dichlorodiphenyldichloroethylene 
scAT; Σ HCH subcutaneous adipose tissue 
T2DM sum of hexachlorocyclohexane; type 2 diabetes mellitus 
vAT visceral adipose tissue 
XE xenoestrogens 
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